Windtree Therapeutics Inc. – Credit Agreements Watch

from 8-K ~20 pages Neither This Security Nor the Securities Into Which This Security Is Convertible Have Been Registered With the Securities and Exchange Commission or the Securities Commission of Any State in Reliance Upon an Exemption From Registration Under the Securities Act of 1933, as Amended (The “Securities Act”), And, Accordingly, May Not Be Offered or Sold Except Pursuant to an Effective Registration Statement Under the Securities Act or Pursuant to an Available Exemption From, or in a Transaction Not Subject To, the Registration Requirements of the Securities Act and in Accordance With Applicable State Securities Laws as Evidenced by a Legal Opinion of Counsel to the Transferor to Such Effect, the Substance of Which Shall Be Reasonably Acceptable to the Company. This Security and the Securities Issuable Upon Conversion of This Security May Be Pledged in Connection With a Bona Fide Margin Account or Other Loan Secured by Such Securities. Dated as Of: October 9, 2025 Original Principal Amount: $[●] Maturity Date: October 9, 2026 Interest Rate: 10% Windtree Therapeutics, Inc. Senior Convertible Promissory Note This Senior Promissory Note Is a Duly Authorized and Validly Issued Senior Promissory Note of Windtree Therapeutics, Inc., a Delaware Corporation (The “Company”), Having Its Principal Place of Business at 2600 Kelly Road, Suite 100, Warrington, Pa 18976 (The “Note””)

from 8-K ~20 pages Neither This Security Nor the Securities for Which This Security Is Exercisable Have Been Registered With the Securities and Exchange Commission or the Securities Commission of Any State in Reliance Upon an Exemption From Registration Under the Securities Act of 1933, as Amended (The “Securities Act”), And, Accordingly, May Not Be Offered or Sold Except Pursuant to an Effective Registration Statement Under the Securities Act or Pursuant to an Available Exemption From, or in a Transaction Not Subject To, the Registration Requirements of the Securities Act and in Accordance With Applicable State Securities Laws. This Security and the Securities Issuable Upon Exercise of This Security May Be Pledged in Connection With a Bona Fide Margin Account or Other Loan Secured by Such Securities. Common Stock Purchase Warrant Windtree Therapeutics, Inc. Warrant Shares: $[●] Initial Exercise Date: July 2, 2025

from 8-K ~20 pages Neither This Security Nor the Securities for Which This Security Is Exercisable Have Been Registered With the Securities and Exchange Commission or the Securities Commission of Any State in Reliance Upon an Exemption From Registration Under the Securities Act of 1933, as Amended (The “Securities Act”), And, Accordingly, May Not Be Offered or Sold Except Pursuant to an Effective Registration Statement Under the Securities Act or Pursuant to an Available Exemption From, or in a Transaction Not Subject To, the Registration Requirements of the Securities Act and in Accordance With Applicable State Securities Laws. This Security and the Securities Issuable Upon Exercise of This Security May Be Pledged in Connection With a Bona Fide Margin Account or Other Loan Secured by Such Securities. Common Stock Purchase Warrant Windtree Therapeutics, Inc. Warrant Shares: $[●] Initial Exercise Date: June 27, 2025

from 8-K ~20 pages Neither This Security Nor the Securities for Which This Security Is Exercisable Have Been Registered With the Securities and Exchange Commission or the Securities Commission of Any State in Reliance Upon an Exemption From Registration Under the Securities Act of 1933, as Amended (The “Securities Act”), And, Accordingly, May Not Be Offered or Sold Except Pursuant to an Effective Registration Statement Under the Securities Act or Pursuant to an Available Exemption From, or in a Transaction Not Subject To, the Registration Requirements of the Securities Act and in Accordance With Applicable State Securities Laws. This Security and the Securities Issuable Upon Exercise of This Security May Be Pledged in Connection With a Bona Fide Margin Account or Other Loan Secured by Such Securities. Common Stock Purchase Warrant Windtree Therapeutics, Inc. Warrant Shares: $[●] Initial Exercise Date: June 24, 2025

from 8-K ~20 pages Neither This Security Nor the Securities for Which This Security Is Exercisable Have Been Registered With the Securities and Exchange Commission or the Securities Commission of Any State in Reliance Upon an Exemption From Registration Under the Securities Act of 1933, as Amended (The “Securities Act”), And, Accordingly, May Not Be Offered or Sold Except Pursuant to an Effective Registration Statement Under the Securities Act or Pursuant to an Available Exemption From, or in a Transaction Not Subject To, the Registration Requirements of the Securities Act and in Accordance With Applicable State Securities Laws. This Security and the Securities Issuable Upon Exercise of This Security May Be Pledged in Connection With a Bona Fide Margin Account or Other Loan Secured by Such Securities. Common Stock Purchase Warrant Windtree Therapeutics, Inc. Warrant Shares: $[●] Initial Exercise Date: June 9, 2025

from S-1/A 24 pages O-Bank Comprehensive Credit Facility Agreement

from 8-K 5 pages Loan Agreement

from 10-K 8 pages Shareholder Loan Agreement Between Cvie Therapeutics Limited and Lee’s Pharmaceutical International Limited 16 November 2018 This Shareholder Loan Agreement Is Made on This 16h Day of November 2018 Between:- A Cvie Therapeutics Limited, a Company With Limited Liability and Incorporated Under the Laws of Republic of China, With Its Registered Office at 11f., No.36, Songren Road, Xinyi District, Taipei City, Taiwan, Republic of China as Borrower (The “Borrower”); And

from 10-K 8 pages Shareholder Loan Agreement Between Cvie Therapeutics Limited and Lee’s Pharmaceutical International Limited October 26 2018 This Shareholder Loan Agreement Is Made on This 24th Day of October 2018 Between:- A Cvie Therapeutics Limited, a Company With Limited Liability and Incorporated Under the Laws of Republic of China, With Its Registered Office at 11f., No.36, Songren Road, Xinyi District, Taipei City, Taiwan, Republic of China as Borrower (The “Borrower”); And

from 10-K 8 pages Shareholder Loan Agreement Between Cvie Therapeutics Limited and Lee’s Pharmaceutical International Limited 20 September 2018 This Shareholder Loan Agreement Is Made on This 20h Day of September 2018 Between:- A Cvie Therapeutics Limited, a Company With Limited Liability and Incorporated Under the Laws of Republic of China, With Its Registered Office at 11f., No.36, Songren Road, Xinyi District, Taipei City, Taiwan, Republic of China as Borrower (The “Borrower”); And

from 10-K 8 pages Shareholder Loan Agreement Between Cvie Therapeutics Limited and Lee’s Pharmaceutical International Limited 24 April 2018 This Shareholder Loan Agreement Is Made on This 24th Day of April 2018 Between:- A Cvie Therapeutics Limited, a Company With Limited Liability and Incorporated Under the Laws of Republic of China, With Its Registered Office at 11f., No.36, Songren Road, Xinyi District, Taipei City, Taiwan, Republic of China as Borrower (The “Borrower”); And

from 10-K 38 pages General Loan Agreement Cp 114 107.01 1 O-Bank Co., Ltd. Notice Complying With Section 1of the Article 8 of the Personal Information Protection Act 1. Please Find the Information on the Purpose of Collecting of Personal Information, Classification of Personal Information Collected and the Time Period, Area, Target and Way of Use Involved in Using the Personal Information Collected Below for Your Review

from 8-K 5 pages Loan Agreement

from 8-K 5 pages Loan Agreement

from 8-K 5 pages Loan Agreement

from 8-K 5 pages Loan Agreement

from 8-K 1 page Amendment to Irrevocable Standby Letter of Credit

from 8-K 5 pages Loan Agreement

from 8-K 5 pages Loan Agreement

from 8-K 5 pages Loan Agreement